VRK2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL13881333	1.00	2/20
SCHEMBL30013787	1.00	2/20
SCHEMBL17257954	0.80	2/20
SCHEMBL17780473	0.77	2/20
SCHEMBL17257955	0.76	2/20
SCHEMBL28395290	0.69	2/20
SCHEMBL17780349	0.68	2/20
SCHEMBL21467544	0.65	2/20
SCHEMBL23252198	0.65	2/20
SCHEMBL31060634	0.64	2/20
SCHEMBL23828194	0.60	2/20
SCHEMBL23828196	0.60	2/20
SCHEMBL12956561	0.59	2/20
SCHEMBL862198	0.59	2/20
SCHEMBL21527053	0.59	2/20
SCHEMBL16160969	0.57	2/20
SCHEMBL17780339	0.56	2/20
SCHEMBL14972118	0.55	2/20
SCHEMBL14457014	0.55	2/20
SCHEMBL28680815	0.55	2/20

Clinical trials — most relevant to VRK2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis	PHASE4	NOT_YET_RECRUITING
Efficacy and Safety of Ivarmacitinib Monotherapy in the Treatment of csDMARDs-IR Rheumatoid Arthritis	PHASE4	NOT_YET_RECRUITING
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion	PHASE4	RECRUITING
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF	PHASE3	COMPLETED
Efficacy and Safety of 0.25% Timolol Gel in Healing Surgical Open Wounds	PHASE2/PHASE3	COMPLETED
Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19	PHASE2	UNKNOWN
Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia	PHASE2	ACTIVE_NOT_RECRUITING
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
Carboplatin Taxol Avastin in Ovarian Cancer (OVCA)	PHASE2	COMPLETED
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer	PHASE2	COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101	PHASE1	WITHDRAWN
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer	PHASE1	COMPLETED
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy	PHASE1	RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients	nan	UNKNOWN
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation	nan	COMPLETED
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction	nan	COMPLETED
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a VRK2 binder may also engage these)

Protein	Name	Similarity
Q8BN21	—	0.993	Q8BN21 →
Q80X41	—	0.972	Q80X41 →
Q2YDN8	—	0.969	Q2YDN8 →
SHPRH	E3 ubiquitin-protein ligase SHPRH	0.968	landscape →
Q7TPQ3	—	0.966	Q7TPQ3 →
F6RIX4	—	0.966	F6RIX4 →
Q8IV63	—	0.966	Q8IV63 →
RIPK1	Receptor-interacting serine/threonine-protein kinase 1	0.964	landscape →
Q8K3G5	—	0.964	Q8K3G5 →
Q9LW62	—	0.963	Q9LW62 →
Q6NRT0	—	0.962	Q6NRT0 →
Q39050	—	0.962	Q39050 →
F1QDI9	—	0.961	F1QDI9 →
Q5XIX3	—	0.961	Q5XIX3 →
Q7TQE7	—	0.961	Q7TQE7 →
Q9ZUP4	—	0.961	Q9ZUP4 →
VRK1	Serine/threonine-protein kinase VRK1	0.961	landscape →
Q8BTH8	—	0.961	Q8BTH8 →
Q5R6Z9	—	0.960	Q5R6Z9 →
D2HHP1	—	0.960	D2HHP1 →
Q5TAX3	—	0.960	Q5TAX3 →
O60934	—	0.960	O60934 →
Q8C4X2	—	0.960	Q8C4X2 →
Q9ESL4	—	0.960	Q9ESL4 →
Q5R4N7	—	0.960	Q5R4N7 →
Q5R4V3	—	0.959	Q5R4V3 →
I0IUP4	—	0.959	I0IUP4 →
P79457	—	0.959	P79457 →
CSNK1G2	Casein kinase I isoform gamma-2	0.959	landscape →
Q8QGV2	—	0.959	Q8QGV2 →